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The microphthalmia transcription factor (MITF), a
basic-helix-loop-helix zipper factor, regulates distinct
target genes in several cell types. We hypothesized that
interaction with the Ets family factor PU.1, whose ex-
pression is limited to hematopoietic cells, might be nec-
essary for activation of target genes like tartrate-resis-
tant acid phosphatase (TRAP) in osteoclasts. Several
lines of evidence were consistent with this model. The
combination of MITF and PU.1 synergistically activated
the TRAP promoter in transient assays. This activation
was dependent on intact binding sites for both factors in
the TRAP promoter. MITF and PU.1 physically inter-
acted when coexpressed in COS cells or in vitro when
purified recombinant proteins were studied. The mini-
mal regions of MITF and PU.1 required for the interac-
tion were the basic-helix-loop-helix zipper domain and
the Ets DNA binding domain, respectively. Significantly,
mice heterozygous for both the mutant mi allele and a
PU.1 null allele developed osteopetrosis early in life
which resolved with age. The size and number of oste-
oclasts were not altered in the double heterozygous mu-
tant mice, indicating that the defect lies in mature oste-
oclast function. Taken in total, the results afford an
example of how lineage-specific gene regulation can be
achieved by the combinatorial action of two broadly
expressed transcription factors.
The MITF1 gene encodes a basic-helix-loop-helix zipper
(bHLH-zip) protein highly related to the TFE3, TFEB, and
TFEC gene products (1–4). Mutations in the human MITF
gene result in the genetic diseases Waardenburg’s syndrome
2A and Tietz syndrome (5, 6). In the rat, homozygous deletion
of the MITF locus causes microphthalmia and pigment defects
as well as an osteopetrosis that resolves with age (7, 8). At least
18 different mutant alleles at the MITF locus have been char-
acterized in the mouse, and these alleles affect, to varying
extents, differentiation of melanocytes, pigmented retinal epi-
thelial cells, mast cells, and osteoclasts (9–11). Thus, MITF can
selectively affect gene expression and differentiation of devel-
opmentally unrelated types of cells. A major interest of our
laboratories is in understanding how MITF selectively acti-
vates target genes in osteoclasts as opposed to other cell types
where the factor is expressed.
Osteoclasts differentiate from a myeloid progenitor to be-
come mature, multinuclear cells capable of resorbing bone (12).
Mice homozygous for the mutant mi allele develop severe os-
teopetrosis caused by a failure of mononuclear precursors to
mature into multinuclear osteoclasts capable of bone resorp-
tion (13, 14). Bone marrow transplantation experiments dem-
onstrate that the mi mutation acts in a cell-autonomous man-
ner (15, 16), and in situ hybridization studies confirm that
MITF is expressed in osteoclasts beginning at the earliest
stages of endochondrial ossification of long bones (17). Under-
standing how MITF regulates gene expression in osteoclasts
may provide insights into the molecular mechanisms that con-
trol terminal differentiation of this specialized cell type.
MITF and the related TFE factors form heterodimers and
homodimers that bind to DNA sequences related to the E-box
motif (CANNTG) shared by many helix-loop-helix transcription
factors. In cell types affected by MITF mutations, MITF acts by
binding to a cis-acting element, TCATGTG, located in the prox-
imal promoters of lineage-specific genes. For example, genes
encoding tyrosinase (melanocytes) and tartrate-resistant acid
phosphatase (TRAP) (osteoclasts) require this cis-element for
cell type-specific regulation (17, 18). These data indicate that
MITF expression alone is likely insufficient to account for the
regulation of selective targets in the different cell types. One
hypothesis to account for MITF action is that in each cell type,
MITF acts in concert with a unique combination of transcrip-
tion factors to affect expression of target genes.
Expression of the Ets family transcription factor PU.1 dis-
tinguishes osteoclasts from melanocytes. PU.1 expression is
limited to hematopoietic lineages and is necessary for differen-
tiation of a number of cell types, in particular B-cells, macro-
phages, and osteoclasts (19, 20). Osteoclast differentiation fails
at a very early stage in mice bearing a targeted disruption of
the PU.1 gene, but PU.1 is expressed at all stages of osteoclast
differentiation in wild-type cells, including in mature multinu-
clear cells (21). In addition, direct interaction between MITF
and PU.1 in vitro has been detected (22).
In this report we present molecular, biochemical, and genetic
evidence showing that PU.1 and MITF physically and function-
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ally interact. We conclude that the interaction with PU.1 is
necessary for MITF to affect osteoclast differentiation and gene
expression.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections—Cells were maintained in Dulbecco’s
modified Eagle’s medium containing 4 mM L-glutamine, 50 g/ml pen-
icillin, 50 g/ml streptomycin, and 5% newborn calf serum (NIH 3T3
and COS-7) or 10% fetal bovine serum (RAW264.7) at 37 °C in 7% CO2.
Differentiation of RAW264.7 cells was optimized using Dulbecco’s mod-
ified Eagle’s medium and 10% fetal bovine serum supplemented with 50
g/ml ascorbic acid (Sigma), 20 ng/ml soluble recombinant human
RANKL/osteoclast differentiation factor (PeproTech, Inc.), and 104
units/ml recombinant human colony-stimulating factor-1 (a gift from
Chiron Corp., Emeryville, CA). For flow cytometry cells were grown
over a period of 5 days, changing the medium on day 2 and day 4.
NIH 3T3 cells were transfected using the calcium phosphate proce-
dure as described previously (23). COS-7 cells were transfected using
Superfect transfection reagent (Qiagen). Cells were plated at 2  106
cells in 100-mm dishes 24 h before the transfections. Cells were trans-
fected with Superfect reagent as described by the manufacturer. Cells
were harvested 24 h after transfection. RAW264.7 cells were trans-
fected by electroporation as described previously (24).
Expression vectors for PU.1 and MITF and the TRAP luciferase
reporter have been described previously (17, 25). Site-directed point
mutations of PU.1 and MITF binding sites, indicated in Fig. 1, were
introduced by PCR (17). The S36T enhanced green fluorescent protein
(GFP) reporter gene-derived pEGFP-1 (CLONTECH) was fused to the
TRAP proximal promoter (from 620 to 3, relative to the ATG codon).
Flow Cytometry of Stably Transfected Cell GFP Reporter Gene Con-
structs—Under low light conditions, cells were suspended in phosphate-
buffered saline and incubated for 10 min at room temperature. Resus-
pended cells were analyzed for GFP expression using a FACSCalibur
flow cytometer (Becton Dickinson). Data analysis was performed by
analyzing 10,000 events for each assay using the CELLQuest software
package (Becton Dickinson). The fluorescence intensity was divided
into four regions, M1–4. M1 was set to encompass the background level
of green autofluorescence exhibited by 99.9% of untransfected control
cells, and M2, M3, and M4 represented logarithmic increments of flu-
orescence intensity (100-fold, 1,000-fold, and 10,000-fold above back-
ground, respectively). All events with fluorescence intensity greater
than the M1 region were accepted as cellular GFP fluorescence events.
The data are presented as follows.
% GFP-expressing cells
M4)
(M2M3M4)
(Eq. 1)
Protein Interaction Assays—COS-7 cells were metabolically labeled
with [35S]methionine for 3 h. Cells were lysed for 30 min at 4 °C in a
lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 6 mM MgCl2, 1%
Nonidet P-40) containing protease (10 g/ml aprotinin, 10 g/ml leu-
peptin, 100 g/ml phenylmethylsulfonyl fluoride) and phosphatase (1
mM EGTA, 10 mM NaF, 1 mM tetrasodium pyrophosphate, 0.1 mM
-glycerophosphate, 1 mM NaVO3) inhibitors. Cell lysates were centri-
fuged, precleared with 20 l of protein G Gamma Bind Plus Sepharose
beads (Amersham Pharmacia Biotech) for 45 min at 4 °C, and incubated
with monoclonal anti-HA antibody (Babco) or polyclonal anti-MITF
serum (raised against amino acids 1–111) overnight. Beads were pre-
cipitated and washed four times with lysis buffer and once with a low
salt buffer (50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 6 mM MgCl2, 1%
Nonidet P-40). Samples were resolved on SDS-PAGE and analyzed by
autoradiography.
The various DNA constructs encoding bacterial fusion proteins were
generated by PCR amplification of PU.1 and MITF cDNAs with PCR
primers defining the boundaries shown in Fig. 5. Both GST vectors
(pGEX, Amersham Pharmacia Biotech) and His6-tagged vectors
(pET15b and pET32, Novagen) were used to make fusion proteins.
Recombinant fusion proteins were purified by affinity chromatography
following protocols supplied by the vector manufacturers. 1 g of the
recombinant GST or GST fusion bait protein was incubated with 20-l
glutathione-Sepharose beads (Amersham Pharmacia Biotech) in bind-
ing buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.5% Nonidet P-40)
in 300 l for 1 h at 4 °C. 1 g of the His6-tagged test protein was then
added to the reaction and incubated for another 2 h at 4 °C. Beads were
precipitated and washed five times with binding buffer. Reaction prod-
ucts were resolved on SDS-PAGE and analyzed by Western blotting
using anti-His6 antibody (Santa Cruz).
Electrophoretic Mobility Shift Assay—EMSAs were performed as
described previously using His6-tagged versions of MITF and PU.1 (17).
The sense strand oligonucleotide, representing the mouse TRAP prox-
imal sequences, was CAGTTCTGGGGAAGTCCAGTGCTCACAT-
GACCCA. The core of the PU.1 site (GGA to TTA) or of the E-box
(CACAGT to CTCGAG) was mutated singly or in combination. The
sense stands of the TRAP promoter and SV40 enhancer oligonucleotides
used in Fig. 1C were CCAGTTCTGGGGAAGTCCAGTGCTC and CT-
GAAAGAGGAACTTGGTTAGGTA, respectively.
Mice and Radiological/Histological Analyses—The mi mutation was
maintained on a B6C3Fe hybrid background as originally obtained from
Jackson Laboratory (Bar Harbor, ME). The PU.1 knockout model was
generously provided by Dr. Harinder Singh (University of Chicago) and
was supplied in the 127J background (26). Mice heterozygous for both
PU.1 and mi alleles were produced and then crossed to supply all
combinations of the two alleles. The PU.1 null allele was genotyped by
PCR as described (27). The mi allele was genotyped by PCR with
primers that allowed the 3-base pair difference between wild-type and
mi allele to be distinguished by gel electrophoresis. There was a 100%
correspondence between eye pigment phenotype and genotype deter-
mined by this PCR method.
Newborn animals were euthanized and fixed in 4% paraformalde-
hyde in phosphate-buffered saline for 48 h at 4 °C, then transferred to
70% ethanol. Radiological analysis was performed on Faxitron x-ray
machine (Hewlett Packard model 43855A) for 1–2 min at 35–45 kV
using X-Omat V film (Kodak). Procedures for histological staining have
been described previously (28).
For TRAP histochemical staining newborn femurs were embedded in
plastic resin using a JB-4 embedding kit (Polysciences, Inc.) as de-
scribed by manufacturer, and 5-m sections were cut using the LKB
Ultratome (LKB Instruments Inc., Rockville, MD). Samples were
stained for TRAP activity using a leukocyte acid phosphatase kit
(Sigma) as described by the manufacturer.
RESULTS
PU.1 Regulates the TRAP Promoter through a Conserved
GGA Binding Site—The proximal promoter of the mouse TRAP
gene contains a conserved binding site for MITF which is nec-
essary for the transcription of the gene during terminal oste-
oclast differentiation (17). A putative binding site for the Ets
family transcription factor PU.1 (GGAA) is located around 10
base pairs upstream of the MITF binding site in the human,
mouse, and pig TRAP genes (Fig. 1A). EMSAs were performed
with this site using purified recombinant PU.1 (Fig. 1B). These
experiments demonstrated that PU.1 specifically recognized
the TRAP promoter probe containing the wild-type binding
site, but not a probe with a mutated binding site (Fig. 1B, lanes
1 and 2). Additionally, PU.1 binding was competed efficiently
by increasing amounts of unlabeled TRAP competitor DNA
representing the wild-type binding site, but not the mutant site
(Fig. 1B, lanes 3–8 versus 9–14).
To confirm that this site is bound by native PU.1, we exam-
ined RAW264.7 macrophage nuclear extracts by EMSA (Fig.
1C). PU.1 is the only macrophage nuclear protein that recog-
nizes the high affinity PU.1 site from SV40 (25). When the
TRAP sequence was used in EMSA a complex was detected
which comigrated with the SV40 PU-box complex (Fig. 1C,
lanes 1 and 2). Addition of anti-PU.1 polyclonal antibody, but
not preimmune serum, could block formation of this complex
(Fig. 1C, lane 4 versus lane 3). By comparison with the SV40
PU-box, the TRAP site was a substantially lower affinity site as
judged by relative cold competition (Fig. 1C, lanes 6–9 com-
pared with lanes 10–13).
The ability of PU.1 to transactivate the TRAP promoter
through this binding site was examined using transient trans-
fection assays (Fig. 2A). In NIH 3T3 cells, which do not express
PU.1, cotransfection of a PU.1 expression vector was able to
activate the TRAP promoter by 4-fold (Fig. 2A, left panel).
When the conserved binding site was mutated, activation by
PU.1 was abrogated (Fig. 2A, left panel). Similar results were
seen when transient assays were performed in RAW264.7 cells
that express endogenous PU.1, and basal activity of the TRAP
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promoter was decreased about 2-fold in this cell type as well
(Fig. 2A, right panel).
Incubation of RAW264.7 cells with colony-stimulating fac-
tor-1 and RANKL can promote the differentiation of osteoclast-
like cells (29). We used this in vitro differentiation system to
examine the role of the conserved PU.1 binding site in regulat-
FIG. 1. PU.1 binds to the conserved GGAA sequence on the TRAP promoter. Panel A, sequences of the TRAP promoter from mouse,
human, and pig contain a conserved PU.1 binding site (GGAA) upstream of the conserved E-box (CACATG). The mutations introduced into the
PU.1 binding site and the E-box are shown in small type above the sequences. Panel B, 100 ng of the recombinant His6-thioredoxin-PU.1 fusion
protein was incubated with 32P end-labeled wild-type (T) or mutant (GGAA to TTAA, ) TRAP promoter. The formation of the complex was
competed with increasing amounts (2-, 5-, 10-, 50-, 100-, 200-fold molar excess, lanes 3–8, respectively) of cold wild-type probe (TRAP) but not with
the same amounts of cold mutant probe (TRAPPU, lanes 9–14). The arrow indicates the PU.1TRAP oligonucleotide complex. Panel C, RAW264.7
nuclear extracts were incubated with 32P end-labeled TRAP (T) or SV40 enhancer (S) oligonucleotides. The effect of adding preimmune rabbit
serum (lane 3) or anti-PU.1 antiserum (lane 4) to PU.1TRAP complex formation is shown. Note that this antibody blocks complex formation rather
than causing a band supershift (25). The formation of the SV40PU.1 complex was competed with increasing amounts of the cold SV40 enhancer
probe (SV40PU, 0, 5-, 25-, 50-, and 100-fold molar excess, lanes 5–9, respectively) or cold TRAP promoter probe (TRAP, same amounts of competitor,
lanes 10–13). The arrow shows the PU.1-containing complex.
FIG. 2. PU.1 transactivates the TRAP proximal promoter. Panel A, NIH 3T3 or RAW264.7 cells (as indicated) were transfected with 5 g
of either TRAP wild-type (WT) luciferase reporter or the TRAP promoter with the mutated PU.1 site (GGAA to TTAA, PU.1). The promoter-
reporter constructs were transfected either alone (PU.1, 0.5 g or 2 g of empty expression vector for 3T3 or RAW264.7, respectively) or together
with PU.1-expressing vector (PU.1, 0.5 g or 2 g of expression vector for 3T3 or RAW264.7, respectively). Promoter activity was expressed as
relative luciferase units relative to the wild-type basal promoter activity (set to a value of 1). The results of four independent experiments
performed in duplicate are represented, and the error bars indicate the standard deviation. Panel B, RAW264.7 cells were stably transfected with
the indicated wild-type and mutated TRAP reporter constructs (either PU.1 or E-box sites mutated), and pooled clones were grown without RANKL
or in the presence of RANKL for 5 days, as indicated. The GFP plasmid without promoter was included as a control. GFP expression was
determined by flow cytometry (see “Experimental Procedures”). The graph represents the percentage of cells exhibiting high fluorescence (103-104
higher than background fluorescence) among all cells with GFP fluorescence. The average of three experiments is shown with error bars indicating
the standard deviation.
Genetic Interactions between MITF and PU.1 36705
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ing TRAP expression during differentiation of RAW264.7 cells
(Fig. 2B). RAW264.7 cells were stably transfected with either a
wild-type TRAP promoter linked to GFP or promoters with the
PU.1 binding site or MITF binding site mutated. Pooled clones
containing each construct were selected and subsequently in-
duced to differentiate for 5 days with colony-stimulating fac-
tor-1 and soluble RANKL. Following this treatment, about 10%
of cells in RAW264.7 cultures were multinuclear osteoclast-like
cells (data not shown). Flow cytometry was used to study GFP
expression in aspirated cells from these cultures (see “Experi-
mental Procedures”). The analysis indicated that the percent-
age of highly fluorescent GFP cells increased 3-fold following
treatment of cultures with RANKL compared with untreated
cultures. Mutation of the PU.1 site in the proximal promoter
reduced GFP reporter activity in RANKL-treated cells by 3-fold
to the level found in untreated cultures (Fig. 2B, TRAPPU.1,
right panel). The PU.1 mutation also had a smaller effect on
reporter activity in untreated RAW264.7 cells (Fig. 2B, left
panel). As a positive control, we reproduced the observation
that mutation of the MITF site resulted in significantly re-
duced TRAP promoter activity following osteoclast differentia-
tion (Fig. 2B, TRAPE, RANKL, 17).
MITF and PU.1 Cooperate in Activation of TRAP Reporter
Genes—To test the hypothesis that interaction with PU.1
might account for the ability of MITF to regulate gene expres-
sion in osteoclasts, the combined ability of the two factors to
activate the TRAP promoter was studied using transient trans-
fection assays. Expression vectors for PU.1 or MITF alone
activated the TRAP reporter 4–5-fold, but the combination of
the two factors activated the TRAP reporter 20-fold (Fig. 3).
When either the E-box or the PU.1 binding site in the TRAP
promoter was mutated, the combination of MITF and PU.1
failed to superactivate the reporter (Fig. 3). The MITF/mi mu-
tation, which encodes a protein lacking the ability to bind to the
conserved TRAP E-box (17), failed to superactivate the TRAP
reporter in combination with PU.1 (Fig. 3). These results imply
a functional interaction between MITF and PU.1 which is
dependent on DNA binding of both transcription factors to the
TRAP promoter.
Physical Interactions between MITF and PU.1—Sato and
co-workers (22) have demonstrated previously that MITF and
PU.1 can physically interact in vitro when bound to DNA. To
confirm and extend these results, biochemical assays were used
to study the physical interaction of the two factors in the
absence of DNA (Figs. 4 and 5). Coimmunoprecipitation of PU.1
and MITF in COS-7 cells was studied (Fig. 4A). Expression
vectors encoding HA-tagged PU.1 and wild-type MITF were
cotransfected into COS-7 cells. HA-PU.1 was immunoprecipi-
tated from cells metabolically labeled with [35S]methionine,
and the immunoprecipitates were examined by denaturing gel
electrophoresis. The experiments demonstrated that a protein
with the same mobility as MITF was coprecipitated with PU.1
(Fig. 4A, arrow). This protein was absent from precipitates
obtained either from cells expressing only HA-PU.1 (Fig. 4A) or
in mock-transfected cells that expressed neither protein (data
not shown). In addition, if preimmune serum was used, or if the
primary antibody was not included in the immunoprecipitation
reaction, neither MITF nor PU.1 was detected (data not
shown).
In a complementary set of experiments, full-length recombi-
nant proteins were expressed in Escherichia coli. His6-tagged
MITF and GST-PU.1 were separately expressed and purified.
GST-PU.1 bound to glutathione-Sepharose beads was used in
“pull-down” assays with His6-tagged MITF (Fig. 4B). These
experiments demonstrated that His6-tagged MITF could bind
to GST-PU.1 Sepharose beads but not to GST-alone beads (Fig.
4B).
To map the domain of MITF involved in the interaction with
PU.1, a series of MITF deletion mutations fused to GST was
tested in pull-down assays using His6-thioredoxin-tagged PU.1
(Fig. 5). The fragment of MITF containing amino acids 199–
298, which included the bHLH-zip domains (Fig. 5A), was able
to interact with PU.1 as efficiently as the full-length protein
(Fig. 5C, top panel). The protein encoded by the MITF/mi allele
was also bound as efficiently as wild-type protein (Fig. 5C, top
panel, last two lanes). Neither the N-terminal region including
the basic domain (amino acids 1–217) nor the C-terminal por-
tion that included the HLH-zip domain (amino acids 217–419)
was able to bind PU.1 above the background level observed
with GST alone (Fig. 5C, top panel). In control experiments the
MITF deletion proteins did not bind to His6-thioredoxin alone
(Fig. 5C, bottom panel). Therefore, both basic and HLH-zip
domains of MITF are necessary for efficient PU.1 binding.
FIG. 3. MITF and PU.1 collaborate to activate the TRAP pro-
moter. NIH 3T3 cells were transfected with the luciferase reporter (5
g) driven by either the wild-type TRAP promoter (WT), or the TRAP
promoter with mutations either in the E-box (CACATG to CTCGAG,
E) or in the PU.1 binding site (GGAA to TTAA, PU). The promoter-
reporter constructs were transfected either alone (with empty expres-
sion vector) or together with vectors expressing 0.5 g of PU.1, 3 g of
MITF, or the combination of 0.5 g of PU.1 and 3 g of MITF. Promoter
activity was expressed as the relative luciferase units with basal activ-
ity set to 1 as above. The results of four independent experiments, each
performed in duplicate, are presented, with error bars indicating the
standard deviation.
FIG. 4. Physical interaction between MITF and PU.1. Panel A,
COS-7 cells were transiently transfected with expression vector for
HA-PU.1, MITF (see “Experimental Procedures”), or both together.
Cells were metabolically labeled with [35S]methionine, and immunopre-
cipitation (IP) reactions were performed using antibodies against the
HA tag or MITF. Reaction products were resolved on 8% SDS-PAGE
and analyzed by autoradiography. Panel B, 1 g of recombinant His6-
MITF was incubated with 1 g of recombinant GST or GST-PU.1. After
incubation with glutathione-Sepharose beads (or Sepharose beads
alone) and washing, bound material was resolved on 8% SDS-PAGE
and analyzed by Western blot using antibodies against the His6 tag.
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PU.1 is a 272-amino acid protein that consists of the
N-terminal activation domain, PEST domain, and C-terminal
DNA binding domain (Fig. 5B; 20). To map the MITF interact-
ing domain of PU.1 a series of deletions fused to His6-thiore-
doxin was constructed and tested in pull-down binding assays
using GST-MITF (amino acids 199–298) as bait (Fig. 5D).
Recombinant PU.1 proteins lacking either the activation do-
main (33–100) or the PEST domain (PEST) were able to
interact with MITF, but the protein without the DNA binding
domain (201–272) lost the ability to bind MITF (Fig. 5D).
To confirm the minimal regions of MITF and PU.1 required
for the interaction, the in vitro binding assay was performed
using amino acids 199–298 of MITF fused to GST (Fig. 5A) and
amino acids 161–272 of PU.1 fused to His6-thioredoxin (Fig.
5B). These experiments demonstrated that the DNA binding
domain of PU.1 was able to bind GST-MITF 199–298 fusion
protein, but not GST (Fig. 5E). Inclusion of ethidium bromide
in these reactions had no effect on the pull-down results, con-
sistent with the conclusion that interaction between free pro-
teins in solution, and not protein bacterial DNA complexes, is
being measured in these assays (data not shown).
PU.1 and MITF Do Not Bind in a Cooperative Fashion to the
TRAP Promoter—A possible explanation for the cooperation
between MITF and PU.1 is that the two factors bind in a
cooperative fashion to target genes like TRAP. To investigate
the mechanism of cooperation between PU.1 and MITF, we
performed an EMSA using a TRAP promoter probe containing
binding sites for both PU.1 and MITF. When both PU.1 and
MITF were present in the reaction, we observed that a new
band with lower electrophoretic mobility was detected, repre-
senting a ternary complex containing PU.1, MITF, and TRAP
promoter sequences.
Mutation of the binding site for either transcription factor
abolished the formation of the complex containing both MITF
and PU.1 (Fig. 6A). Cold competition experiments to measure
off time rates of the complexes were also performed (Fig. 6B).
Consistent with the data presented above, the PU.1 complex
had a very rapid off rate of less than 30 s. The MITF complex
was very stable, with little competition observed even after 30
min. The complex containing both factors behaved the same as
the PU.1 complex, with a very rapid off rate (Fig. 6B). Taken
together, the data indicate that the presence of MITF, which
binds stably and with high affinity, does not alter the low
affinity binding of PU.1 to the adjacent site.
Genetic Interaction between MITF and PU.1—Ultimately,
the relevance of interactions between MITF and PU.1 can only
be assessed by examining interactions at the genetic level in
intact animals, where both the target cell population and the
levels of expression of the gene products are appropriate. Mice
heterozygous for either the mi allele (MITF/mi) or for a PU.1
knockout allele do not develop an apparent bone phenotype. To
test for the possibility of genetic interaction between MITF and
PU.1 we crossed heterozygous MITF/mi mice with heterozy-
gous PU.1/ mice to obtain double heterozygous MITF/mi/
PU.1/ animals. The resulting mice were analyzed for bone
density and morphology by radiological techniques and hema-
toxylin and eosin staining (Figs. 7, A and B, respectively).
Approximately 25% of the double heterozygous MITF/mi/
PU.1/ mice were clearly osteopetrotic compared with 0% of
PU.1/ and 5% of MITF/mi single heterozygotes, respectively
FIG. 5. Identification of MITF and PU.1 interacting domains. Panel A, diagram of MITF, indicating protein domains expressed as GST
fusion proteins in E. coli. The position of the mi mutation, a deletion of one of four critical arginine residues in the basic region, is indicated (arrow).
LZ, leucine zipper. Panel B, diagram of PU.1 indicating protein domains expressed as His6-thioredoxin fusion proteins in E. coli. In panels C–E,
the binding reactions with recombinant proteins were incubated with glutathione-Sepharose beads (or Sepharose beads alone) and washed; bound
material was eluted and resolved on 10% SDS-PAGE and analyzed by Western blotting using antibodies against His6 tag (Santa Cruz
Biotechnology). DBD, DNA binding domain; AD-activation domain. Panel C, 1 g of recombinant His6-thioredoxin-PU.1 (PU.1) or His6-thioredoxin
(Trx) was incubated with 1 g of recombinant GST or GST-MITF fusion proteins, as indicated. MITF-mi represents full-length MITF protein with
the 3-base deletion that defines the mi allele. Panel D, 1 g of recombinant PU.1 or PU.1 deletion mutants (Fig. 5B) fused to His6-thioredoxin or
His6-thioredoxin alone (Trx) was incubated with 1 g of recombinant GST or MITF bHLH-zip fused to GST (amino acids 199–298). Panel E, 1 g
of PU.1 DNA binding domain (amino acids 161–272) fused to His6-thioredoxin or His6-thioredoxin alone (Trx) was incubated with 1 g of
recombinant GST or GST fused to the bHLH-zip domain of MITF (amino acids 199–298).
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(Table I). Although the osteopetrosis in the double heterozygote
mice was detected readily at birth, it resolved with age so that
eruption of teeth occurred, and by sexual maturity bone density
as assayed by radiography appeared normal (data not shown).
Surprisingly, we found that mice of genotype PU.1/ also
survived to birth. The PU.1/ strain used in this report has
previously been found to die in utero because of severe hema-
tological abnormalities (26). The number of mice surviving was
lower than predicted for mice that of genotype PU.1/;mi/mi
and PU.1/;MITF/mi (10 and 50% of expected numbers, re-
spectively, Table I). The PU.1/ mice that survived exhibited
osteopetrosis (Fig. 7).
Osteoclasts in sections from animals of the various genotypes
were visualized by histochemical staining for TRAP activity
(Fig. 7C). The results showed that in mi/mi mice numerous,
small osteoclasts were detected, whereas in PU.1/ mice no
TRAP-positive osteoclasts were detected, in accordance with
previous reports for both types of models (14, 21). In the double
heterozygote mutant mice that developed osteopetrosis, the
morphology and number of osteoclasts were not significantly
different from those in the wild-type (Fig. 7C).
DISCUSSION
MITF and PU.1 Interact during Osteoclast Differentiation—
One possible mechanism that could account for the selective
regulation of osteoclast target genes is that MITF might coop-
erate with a hematopoietic cell-restricted factor in this cell
type. Results from both transfection studies and from in vitro
biochemical assays support the hypothesis that the Ets family
factor PU.1 and MITF act together to regulate the mature
osteoclast marker gene, TRAP. Consistent with the biochemi-
cal data, combining mutant alleles for MITF and PU.1 in mice
demonstrated an interaction between these two genes in vivo
during osteoclast differentiation.
Osteopetrosis was detected early in life in mice heterozygous
for a PU.1 knock-out allele and the mi allele. The morphology
and number of osteoclasts appeared normal in bone sections
examined in the compound heterozygous mice, indicating that
the defect occurred during the later stages of osteoclast differ-
entiation or in fully mature osteoclasts. The similar phenotypes
of mice with targeted deletions of two known MITF target
genes, TRAP and cathepsin K, support a role for both MITF
and PU.1 in mature osteoclasts (17, 30–32). Multinuclear os-
FIG. 6. MITF and PU.1 form a ternary complex on the TRAP
promoter. Panel A, MITF and PU.1 binding to the TRAP promoter was
not cooperative in vitro. 100 ng of recombinant His6-thioredoxin-PU.1
fusion protein and 100 ng of recombinant His6-MITF protein were
incubated with 32P end-labeled wild-type (Wt), GGAA to TTAA mutant
(Mt-PU.1), CACATG to CTCGAG mutant (Mt-E), or double mutant
(Mt-PU.1E) TRAP promoter oligonucleotides (see “Experimental Pro-
cedures”). The location of the MITFPU.1pTRAP complex is indicated
with an arrow. Panel B, 100 ng of recombinant His6-thioredoxin-PU.1
fusion protein and/or 100 ng of recombinant His6-MITF protein was
incubated with 32P end-labeled wild-type TRAP promoter oligonucleo-
tides (see “Experimental Procedures”). A 200-fold molar excess of the
cold TRAP oligonucleotide was added to the reaction mix either before
the addition of the labeled probe () and incubated for 3 min, or after
the addition of the labeled probe and incubated for 0.5, 2.5, 5, 10, 15, 20,
or 30 min, as indicated. The location of the MITFPU.1TRAP complex is
indicated with an arrow.
FIG. 7. Osteopetrotic phenotype of double heterozygous MITF/
mi/PU.1/. Panel A, radiological analyses of the femur from mice of
the genotype indicated. High density areas of the unresorbed calcified
tissue in double heterozygous PU.1/ and mi/mi samples are indi-
cated by arrows. Panel B, histological staining of the femur sections
from mice of the genotypes indicated. Eosin-stained unresorbed calci-
fied tissue in double heterozygous PU.1/ and mi/mi samples is
indicated by arrows. Samples were observed at a magnification of100.
Panel C, osteoclasts from femur sections from mice of the indicated
genotypes were detected by TRAP histochemical staining in situ. Sam-
ples were observed at a magnification of 400.
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teoclasts are present in both TRAP and cathepsin K knock-out
models, but these osteoclasts are not fully functional, and mild
osteosclerotic disease occurs in the mice (31, 32). The inability
to regulate expression of these MITF target genes properly
could account for the phenotype reported here (17, 30). It is
worth noting that the cathepsin K promoter region shown to be
necessary for MITF regulation also contains consensus PU.1
recognition sequences (30).
Approximately 25% of double PU.1/mi heterozygotes devel-
oped the osteopetrotic phenotype. The incomplete penetrance of
the phenotype may reflect genetic redundancy in osteoclast
differentiation and partial compensation for the loss of PU.1
and MITF function by other genes involved in this process. An
alternate possibility is that these results may reflect that the
experiments were performed in an outbred genetic background
resulting from the F2 cross of the unrelated MITF/mi and
PU.1/ lines, and that genetic modifiers specific for either
PU.1 or MITF alter the penetrance of the observed phenotype.
The potential role of genetic background is supported by the
unexpected survival of PU.1/ mice until birth. Two PU.1
knock-out models have been generated, and different pheno-
types have been observed (26, 33). In the mice generated by
Maki and colleagues (33), mice survive postpartum but suc-
cumb rapidly to microbial infections unless maintained with
antibiotics or rescued by bone marrow transplantation. In the
mutant allele used in the experiments reported here, lethality
was observed at days 16–18 of embryonic development because
of severe hematological abnormalities (26).
The less penetrant PU.1 null phenotype has been attributed
to incomplete functional disruption of the PU.1 gene (19), but
the effect of the genetic background suggested by the results
presented here has not been reported previously. We found that
50% of PU.1 homozygous null mice were born. These mice
died in the 1st week of life, similar to the other PU.1 knock-out
model (33), and these mice also developed severe osteopetrosis
typified by a lack of osteoclasts in developing bone, the same
phenotype reported for the other PU.1 knock-out model (21).
The results argue for the existence of genetic modifiers that
reduce the penetrance of a PU.1 null mutation, with MITF as
one potential candidate modifier. Fewer PU.1 null mice sur-
vived to birth than predicted when they were homozygous for
the mi allele, and we have demonstrated previously that MITF
is expressed prior to PU.1 in embryonic macrophages (34).
The related transcription factors TFE3 and TFEC, both ex-
pressed in osteoclasts (4), could be potential modifiers of MITF.
Based on biochemical data, it has been hypothesized that TFE3
may modify the osteopetrotic phenotype observed in rats ho-
mozygous for the microphthalmia blanc allele, a recessive al-
lele containing a large deletion of the rat MITF gene (8). The
osteopetrotic phenotype of this rat resolves with age, similar to
the phenotype of the double mi/PU.1 heterozygotes (7, 8). Sim-
ilarly, other Ets family transcription factors expressed in the
macrophage lineage (e.g. Ets-2, ELF-1, MEF, 35, 36), some of
which can also trans-activate the TRAP promoter2, could ame-
liorate the effects of the absence of PU.1. Additional biochem-
ical and genetic analyses will be required to determine the role
of these bHLH-ZIP and Ets factors as well as to identify other
putative PU.1 and MITF partners in osteoclast differentiation.
The Mechanism of MITF and PU.1 Collaboration—PU.1 in-
teractions with several different transcription factors have
been documented (37). For example, PU.1 recruits the tran-
scription factor PIP to DNA through direct physical interac-
tions, an event necessary for activation of target genes in B-
cells (38–40). These results led us to anticipate that MITF and
PU.1 might bind cooperatively to DNA, but all evidence ob-
tained here indicated that PU.1 and MITF bound independ-
ently to TRAP promoter sequences. Because MITF and PU.1
are coexpressed in both macrophages and osteoclasts, a mech-
anism based on cooperative DNA binding might lead to inap-
propriate expression of genes like TRAP in macrophages. Fur-
ther, if the two factors bind to DNA independently, the weak
TRAP PU.1 binding site may provide a mechanism by which
TRAP promoter activity is sensitive to the increased PU.1
expression levels observed during osteoclast differentiation
(21).
Binding sites for both PU.1 and MITF were required for
superactivation of the TRAP promoter, indicating that a ter-
nary complex with DNA might be requisite for functional in-
teractions to occur. By contrast, the bHLH factor MyoD and its
cofactor for regulation of muscle-specific genes, MEF2, require
only a single binding site for either factor to allow synergistic
activation of target genes (41). The active ternary complex
formed when both factors bind to DNA may result in confor-
mational changes in both proteins which allows for more effi-
cient interaction with transcriptional coactivators. PU.1 and
MITF have both been shown to be targets of signaling path-
ways in other cell types (39, 42, 43). Modification of either
MITF or PU.1 by signaling pathways could also enhance the
formation of the ternary complex and couple complex formation
to signals triggering osteoclast differentiation.
Other mechanisms that depend on PU.1 and MITF interac-
tion prior to DNA binding cannot be ruled out by our data. The
overexpression of MITF/mi can lead to retention of PU.1 in the
cytoplasm of transfected WEHI-3 cells (22). The formation of a
PU.1MITF complex in the cytoplasm and cotranslocation into
the nucleus could ensure that the two factors are recruited
together to promoters such as TRAP, effectively increasing the
on rate for binding and the likelihood that both sites on the
promoter are occupied. Such a mechanism could also be regu-
lated by post-translational modification of either or both
factors.
2 A. I. Cassady and D. A. Hume, unpublished data.
TABLE I
Genotypes and phenotypes of mice carrying mi and PU.1 null alleles
PU.1a
genotype
MITFa
genotype
Actual no.
of mice
Predictedb no.
of mice
No.
of op
mice
% op
mice
/ MITF/MITF 19 (12.8%) 9.25 (6.25%) 0 0
/ MITF/MITF 29 (19.5%) 18.5 (12.5%) 0 0
/ MITF/mi 42 (28.3%) 37 (25%) 10 24
/ MITF/mi 21 (14.1%) 18.5 (12.5%) 1 5
/ mi/mi 5 (3.3%) 9.25 (6.25%) 5 100
/ mi/mi 16 (10.8%) 18.5 (12.5%) 16 100
/ mi/mi 1 (0.6%) 9.25 (6.25%) 1 100
/ MITF/MITF 6 (4.5%) 9.25 (6.25%) 6 100
/ MITF/mi 9 (6.1%) 18.5 (12.5%) 9 100
a MITF/mi/PU.1/ double heterozygous mice were crossed, and offspring were genotyped as described under “Experimental Procedures.”
b Predicted numbers are based on a Mendelian inheritance of unlinked genes and a total of 148 mice analyzed.
Genetic Interactions between MITF and PU.1 36709
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
In summary, we have shown that PU.1 and MITF cooperate
to activate the process of osteoclast differentiation and tran-
scriptional activation of the osteoclast-specific TRAP gene.
These findings add to the increasing evidence that unique
combinations of widely distributed transcriptional regulators
like MITF and PU.1 can generate lineage-restricted gene
expression.
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